AGR announces collaboration with MegaMed Clinical Research.
Bangkok, Thailand (June 1st, 2010) - Asia Global Research (AGR), a leading clinical research organization (CRO) in Asia, announces its latest collaboration with MegaMed Clinical Research. As part of the partnership, AGR will provide SMO services to MegaMed Clinical Research in many Asian countries.
MegaMed Clinical Research is a medical institution conducting clinical trials and research in multiple therapeutic areas in North America, Europe, Middle East and Russia. Their Toronto and Chicago outpatient facilities are fully equipped and are ideal sites to conduct Phase II, Phase III, and Phase IV clinical trials.
Dr. Anthony Alsayed, MegaMed’s CEO and Research Director said “Partnership with AGR will enhance our access to a large study population in many Asian countries. This will ensure the increased likelihood of enrollment goals being met in the shortest period of time.”
“We are delighted in working with such an experienced company like MegaMed Clinical Research as their core values are very similar to ours at AGR,” said James Mash, CEO, AGR. “With this collaboration, AGR will provide qualified, experienced principals investigators for MegaMed’s clinical trials.
This collaboration will allow AGR to expand its geographic coverage to conduct clinical studies in Russian and Eastern Europe”
About AGR:
AGR is a subsidiary of Bumrungrad Hospital Public Company Limited (SET:BH), based in Bangkok, Thailand. Through its CRO and SMO business segments, the Company offers a broad range of Phase I to IV clinical trials, BE study and staffing. AGR’s trial management capabilities include establishing and monitoring trials in Thailand, Vietnam, Malaysia, the Philippines, China, India and the Middle East. Further information is available at www.agr-cro.com or email info@agr-cro.com |
